Asia Fresh News

Asia Fresh Stories

Frost & Sullivan Lauds ClearFlow’s ACT® Technology as a Transformational Force in Post-operative Cardiothoracic Surgery Protocols

leave a comment »

ClearFlow places heavy emphasis on enhancing global customer awareness about PleuraFlow® ACT® System’s role in minimizing RBS

SANTA CLARA, California /PRNewswire/ — Based on its recent analysis of the retained blood syndrome solutions market, Frost & Sullivan recognizes ClearFlow, Inc. with the 2017 Global Frost & Sullivan Award for New Product Innovation. ClearFlow has disrupted post-operative cardiothoracic surgery care with its unique PleuraFlow® Active Clearance Technology® (ACT®) System. Clinical data indicates that this pioneering technology reduces retained blood syndrome (RBS) by 43% and postoperative atrial fibrillation by 33%, giving hospitals considerable return on investment in terms of improved patient outcomes and fewer associated complications. An analysis of over 313,000 US Adult cardiac surgery patients has shown that these complications generally cost an average of $28,814 per incident.

ClearFlow, Inc.
ClearFlow, Inc.

“The PleuraFlow ACT® System comprises a tube clearance apparatus that inserts between the chest tube and the drainage canister outside the body, allowing cardiac ICU staff to minimize the chance of the drainage tube clogging at the bedside,” said Frost & Sullivan Senior Industry Analyst, Patrick Riley. ClearFlow uses silicon for its chest tubes because the softer material is much more comfortable for the patient and causes less pain during removal than conventional hard plastic tubes.

ClearFlow offers four standard French (FR) configurations—20-FR, 24-FR, 28-FR, and 32-FR. It recently released a pediatric edition of its 20-FR System, which has a shorter effective drainage length (SEDL) and fewer drainage holes for use in a smaller chest cavity. The 20-FR SEDL can be used in two-thirds of pediatric applications. The company is developing additional smaller tube configurations for the remaining one-third.

ClearFlow places a considerable emphasis on educating cardiac surgeons, physician assistants, and nursing staff members within the cardiac surgery suite and ICU. It also developed a simple cost calculator application leveraging industry studies and medical payment record databases that allow hospitals to estimate the overall cost savings enabled by the PleuraFlow ACT®. This is in addition to the company’s continuous quality improvement (CQI) program that helps hospitals compare patient results before and after using the PleuraFlow ACT® to track their individual return on investment.

“ClearFlow’s largest market is in the United States, but it has gained regulatory approval to sell the PleuraFlow ACT® System in Australia, Canada, and many more countries in the European Union and South America,” noted Riley. “Clearly, the PleuraFlow ACT® is uniquely positioned for sustained success as it meets customers’ core requirements of quality, functionality, and reliability.”

Each year, Frost & Sullivan presents this award to the company that develops an innovative product to leverage leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which in turn raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About ClearFlow, Inc.

ClearFlow, Inc. is an Anaheim, CA based medical device company that has developed a patented active blood and fluid evacuation system to speed recovery, reduce complications and lower healthcare costs related to medical tube obstruction. The company has been awarded several prestigious awards, including the European Association of Cardiothoracic Surgeons Techno-College Innovation Award for worldwide innovation that has the potential to change the standard of care in heart and lung surgery, and the Innovations in Cardiovascular Interventions Award, among others.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.


Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003

Source: Frost & Sullivan
Related Links:

Written by asiafreshnews

March 29, 2017 at 2:31 pm

Posted in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: